The combination medicine is applied across domains where additional symptomatic support is needed by addressing both the disruptive cough symptoms and associated congestion. This formulation is commonly used in conditions presenting with acute episodes and symptoms related to inflammatory or irritative states, and to help address bothersome mucus.

This combination is generally applied in scenarios where additional management of discomfort is required, commonly used across conditions presenting with acute episodes and symptoms related to inflammatory or irritative states. The therapeutic approach is relevant for managing symptom clusters that may become intense or disruptive, focusing on persistent, non-productive coughing and the presence of thick, tenacious secretions.

Symptomatic Management and Benefits

This medication is relevant for managing symptoms that interfere with daily comfort and physical strain. The combination is used to provide supportive relief that helps ease the overall symptom burden of these disruptive manifestations simultaneously. The combination supports the patient by addressing symptoms related to thick mucus and reducing heightened physiological activity related to coughing. This provides supportive relief by contributing to an easier experience of clearing phlegm.

Quick Fact	Relief for
Dual Discomfort	Persistent Cough and Viscous Congestion

Regulatory References

1. Official FDA Labeling via DailyMed

Eligibility scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults 18 years of age and older are the primary labeled population for this prescription combination.
Populations for whom use is not recommended	Adolescents (12 to 18 years) with compromised respiratory function, such as those with severe lung disease, obesity, or obstructive sleep apnea.
Populations for whom use is contraindicated	Children younger than 12 years of age; breastfeeding women; and individuals known as ultra-rapid metabolizers of Codeine (CYP2D6 polymorphism).

Age-related eligibility rules: Use is strictly contraindicated in children below 12 years and in pediatric patients younger than 18 years following tonsillectomy or adenoidectomy. Prescription use is primarily limited to adults 18 years and older.

Condition-specific eligibility rules: The medicine is contraindicated for patients with significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction (e.g., paralytic ileus), and those taking Monoamine Oxidase Inhibitors (MAOIs). Caution is required for older adults and patients with impaired hepatic or renal function.

Pregnancy and lactation eligibility status: Use is absolutely contraindicated during lactation. Use during pregnancy is documented as having the potential to cause fetal harm.

---

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by establishing mandatory prohibitions based on age and patient physiology, due to the Codeine component. The profile applies absolute contraindications to populations most vulnerable to the risks of opioid exposure, while formal caution is applied to patients with existing organ or respiratory compromise.

Interactions with other medicines and products

This section outlines the officially documented interaction profile of Resyl mit Codein, which is primarily driven by the opioid component, Codeine, and its metabolism.

Classification	Interacting Substance/Category	Officially Documented Effect
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Prohibited for concurrent use and within 14 days of cessation due to risk of serious CNS effects.
Contraindicated	Alcohol	Risk of additive central nervous system (CNS) depression, potentially leading to profound sedation, respiratory depression, coma, and death.
Pharmacokinetic	CYP2D6 Inhibitors (e.g., quinidine, fluoxetine)	Decrease in the active metabolite (morphine) plasma concentration, which may result in reduced efficacy.
Pharmacokinetic	CYP3A4 Inhibitors (e.g., macrolide antibiotics)	Increase in codeine plasma concentrations, potentially leading to greater morphine levels and increased risk of adverse reactions.
Pharmacodynamic	CNS Depressants (e.g., Benzodiazepines, general anesthetics, other opioids)	Risk of additive CNS depressive effects, including severe sedation and respiratory depression.
Pharmacodynamic	Serotonergic Drugs (e.g., SSRIs, SNRIs)	May result in the development of serotonin syndrome.
Drug-Lab Test	Guaifenesin	May interfere with colorimetric assays for 5-HIAA (5-hydroxyindoleacetic acid) and VMA (vanillylmandelic acid), causing false test results.

Officially, patients identified as CYP2D6 Ultra-Rapid Metabolizers (UMs) are noted to convert codeine to morphine more rapidly and completely, resulting in higher than expected active metabolite levels. This population-specific metabolic constraint heightens the risk of respiratory depression. The profile also advises to avoid co-administration with Mixed Agonist/Antagonist Opioid Analgesics (e.g., pentazocine, nalbuphine) as they may reduce the antitussive effect or precipitate withdrawal symptoms.

The pharmacological profile of Resyl mit Codein involves two distinct, complementary mechanisms that modulate the central cough reflex and peripheral airway secretions.

Central Suppression of the Cough Reflex

This domain covers the action of Codeine on the central nervous system. Codeine's active metabolite acts as an agonist on mu-opioid receptors in the brainstem's medulla oblongata, initiating an inhibitory cascade that decreases the excitability of the cough center. This action decreases the excitability of the cough center, resulting in a dampening of the neural signals that propagate the cough pattern.

Peripheral Modulation of Airway Secretions

This domain addresses the effect of Guaifenesin on the respiratory system. It acts peripherally, likely via a gastro-pulmonary reflex, to stimulate bronchial glands. This engagement with peripheral secretory mechanisms increases the volume and reduces the viscosity of respiratory tract fluid. This change to the secretions lowers the mucus viscosity, resulting in an enhancement of mucociliary transport.

Complementary Mechanism Synergy

The drug engages mechanisms across central and peripheral domains. The central inhibition of the reflex and the peripheral alteration of secretion properties provide complementary modulation of the respiratory system. This complementary action modulates both the central nervous system and peripheral secretion pathways.

How to Use Resyl mit Codein

The Codeine/Guaifenesin combination product is administered exclusively via the oral route as a liquid solution, syrup, or drops, following specific dosing schedules outlined in regulatory labeling. The core principle governing its use is the employment of the lowest effective dosage for the shortest necessary duration.

Administration and Dosage

The liquid formulation requires precise measurement to ensure accurate dosing. Administration must be performed using a calibrated milliliter measuring device; household spoons are not appropriate for measuring the volume.

The standard adult regimen for the oral solution typically involves taking 10 mL (containing Codeine 20 mg / Guaifenesin 200 mg) every four hours. In jurisdictions where drops are available, the standard dosage may be 20 to 30 drops, administered three to four times daily. The mandated minimum interval between any two doses is four hours.

Maximum Limits and Duration

To control systemic exposure, a strict maximum daily dose is enforced. For the oral solution, total intake must not exceed 60 mL within a 24-hour period. Where authorized for short-term, non-prescribed use, the maximum permitted duration is often limited to three days.

Population-Specific Constraints

The use of prescription medicines containing Codeine for cough and cold is contraindicated in children younger than 12 years of age. Dosing requires adjustment for specific patient groups: for those with severe liver impairment or severe renal insufficiency, the time interval between doses must be lengthened to reduce the overall daily frequency.

Research Evidence / Overview of Studies for Resyl mit Codein

---

Evidence for use in Cough Relief Associated with Respiratory Infections

Resyl mit Codein was studied for use in conditions associated with acute or disruptive episodes, specifically cough linked to common respiratory infections. Research has explored the outcomes related to physical discomfort, monitoring how cough frequency and intensity change over defined time intervals.

The studies conducted for this indication include controlled trials, where individuals receiving the study medication were compared to those receiving a placebo (a non-active substance). These trials aim to monitor how the ingredients relate to patient-reported outcomes describing perceived discomfort.

Findings indicate that research explored whether the active ingredients were associated with changes in the number and severity of coughing spells in the observed populations. Research highlights changes measured during the study period in outcomes describing episodic or acute changes in cough symptoms. However, the follow-up durations were limited, focusing primarily on short-term symptom changes during the immediate illness period. Studies often do not contain sufficient evidence to compare the findings of this medication directly with those of other short-term treatments.

Evidence for use in Short-Term Symptomatic Treatment of Irritative Cough

This use was evaluated in research contexts involving fluctuating or unstable symptoms related to dry or irritative cough of varying causes. Studies focused on outcomes capturing phases of heightened symptom activity, seeking to understand if the medication can be associated with temporary relief. Research examined short-term changes in outcomes linked to inflammatory or irritative states. The data show patterns observed in studies that focused on the cough reflex related to dry, non-productive cough.

---

Long-term Studies and Follow-up

Research describes the use of Resyl mit Codein as a short-term approach to symptoms. Therefore, specific clinical trials tracking outcomes for periods longer than the study window are not fully established. Evidence available for long-term use is limited.

What is Still Uncertain about Resyl mit Codein

The body of research, while providing insight into short-term changes, still contains significant gaps. Furthermore, certain questions around the optimal approach for conditions presenting with cycles of stability and flare-ups or when symptoms are very low intensity are still uncertain. While studies explored its use during episodes where symptoms become more noticeable, the findings were mixed in certain small groups. This section highlights what is known — and what is still uncertain — about the full picture of the medication's use based on available research.

Common questions about Resyl mit Codein (FAQ)

Q: What is Resyl mit Codein actually prescribed for?

According to official documents, Resyl mit Codein is described as being indicated for relieving cough. The Codeine component is understood to act as an opioid cough suppressant, and the Guaifenesin component as an expectorant to help loosen mucus in the airways.

Q: Is Resyl mit Codein primarily a cough medicine or a pain reliever?

Official product information describes this medication as a combination of an opioid cough suppressant and an expectorant used primarily to relieve cough. While codeine is an opioid, regulatory labeling primarily focuses the intended purpose on the relief of cough.

Q: Can Resyl mit Codein be used to treat symptoms of a common cold or flu?

The medication is described as indicated for relieving cough and loosening mucus. These symptoms are often associated with conditions like the common cold or flu. Official guidance focuses the medication’s authorized use on the relief of the cough itself.

Q: Can individuals with high blood pressure safely use Resyl mit Codein?

Official warnings and precautions sections advise caution for individuals with pre-existing cardiovascular disease, which includes high blood pressure (hypertension). Individuals with these conditions are typically advised to consult with a prescriber regarding use.

Q: Is Resyl mit Codein appropriate for use during pregnancy?

Official information indicates that prolonged use of opioids during pregnancy is associated with a risk of the neonate developing physical dependence. Given these constraints, no formal pregnancy category is assigned by the FDA. Usage is described as needing to be assessed on a case-by-case basis by a qualified professional.

Q: Is Resyl mit Codein safe for women who are breastfeeding?

Use is generally not recommended by regulatory agencies. Official warnings highlight the risk of the Codeine component passing into breast milk, which may lead to serious adverse effects in the nursing infant, such as excessive sleepiness or breathing problems.

Q: Does Resyl mit Codein interact with commonly used over-the-counter pain relievers?

Official guidance recommends using caution when combining this medicine with any other prescription or nonprescription (OTC) products. This is advised to avoid potential drug interactions and to ensure that maximum recommended doses of any overlapping ingredients are not exceeded.

Q: Are there any warnings regarding taking Resyl mit Codein with herbal supplements?

Regulatory guidance describes the importance of providing a complete list of all current medicines and products, including herbal supplements, to a healthcare professional. This practice is advised to help identify and avoid any possible drug interactions.

Q: Are there specific warnings about combining Resyl mit Codein with antidepressant medications?

Official regulatory documents list potential interactions with several types of antidepressants, including MAOIs and serotonergic drugs. Combining these medications may increase the risk of serious side effects like Serotonin Syndrome or profound central nervous system (CNS) sedation.

Q: Is Resyl mit Codein classified as a controlled substance in most regions?

Yes, due to the Codeine component, the medication is classified as a controlled substance. Products containing limited quantities of codeine for cough are commonly described as being categorized within the lower drug schedules (such as U.S. Schedule III or V), depending on the jurisdiction and concentration.

Q: Does the medicine contain any ingredients known to trigger common allergies?

Official documents state that patients should review the full list of inactive ingredients, or excipients, with their pharmacist. This is important because some liquid forms may contain ingredients, such as derivatives of benzyl alcohol, that could potentially trigger allergic reactions in sensitive individuals.

Q: Where can I find the official regulatory documents for Resyl mit Codein?

Official regulatory documents can be found on the websites of various governmental regulatory agencies. These documents include the Summary of Product Characteristics (SmPC) in Europe or the DailyMed labels provided by the U.S. FDA.

Q: Why are there discussions about restricting codeine-containing medicines internationally?

International warnings and regulatory discussions are driven by the documented risk of serious adverse effects related to codeine use. These risks include respiratory depression, which is particularly heightened in certain patient populations, such as children and individuals known as ultra-rapid metabolizers.

Q: Is Resyl mit Codein available for purchase over the counter or is it prescription only?

The status of the drug (prescription vs. over-the-counter) is dependent on the specific dose concentration and the regulations of the local jurisdiction. In many regions, due to the Codeine component, this combination product is categorized as prescription-only.

Q: What are the official recommendations for the proper storage of Resyl mit Codein at home?

According to the official patient information, the medication should be stored at room temperature, typically between 15 C and 30 C. Official recommendations state that it should be kept in a tightly closed container away from moisture, heat, and light, and securely stored out of the reach of children.

Q: Does the effectiveness of Resyl mit Codein decrease over time with regular use?

Official safety warnings indicate that prolonged use of this medication can lead to tolerance. This is understood to mean that over time, the body may become less responsive, and the drug's effectiveness in providing cough relief may diminish.

Q: What should be done in case of a missed dose according to the manufacturer's information?

Regulatory instructions describe a protocol where a missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the patient should resume their regular schedule without doubling the amount.

Q: Is Resyl mit Codein known to cause dry mouth or throat?

Yes, official adverse effect lists indicate that dry mouth is one of the possible common side effects associated with this combination medication. This is documented under the list of common reactions.

Q: Are there specific warnings for the elderly population using Resyl mit Codein?

Official warnings describe the need for caution regarding use in the elderly population. Older adults may exhibit increased sensitivity to the medication's central nervous system effects, such as confusion, dizziness, and slow breathing.

Q: Does Resyl mit Codein contain sugar or is it sugar-free?

Liquid formulations of the medication may contain sugar, as well as other inactive ingredients like alcohol or aspartame. Patients with medical conditions like diabetes are advised to consult with a health professional to review the specific excipient list.

Q: Does Resyl mit Codein affect a person's ability to drive or operate machinery?

This medication commonly causes side effects like dizziness, drowsiness, and impaired judgment. Regulatory warnings describe that patients should refrain from driving or operating heavy machinery until they are certain of how the drug affects them.

Q: What signs might indicate an allergic reaction to Resyl mit Codein?

Official information indicates that signs of a hypersensitivity or allergic reaction may include skin manifestations. These commonly reported signs include skin rash, itching, hives, or swelling of the face, lips, tongue, or throat.

Q: Can people who have asthma or other respiratory issues take Resyl mit Codein?

Regulatory documents advise caution for individuals with pre-existing breathing disorders such as asthma or COPD. Furthermore, the medication is often contraindicated, or forbidden, in patients experiencing severe or acute lung problems, such as severe respiratory depression.

Q: What is the expected duration of effect after a single use of Resyl mit Codein?

The minimum interval between doses is typically recommended as four hours. While the explicit duration of effect may not be stated in patient information, this dosing interval is often reflective of the expected duration of the antitussive relief provided by the medication.

Q: What might happen if someone abruptly stops using Resyl mit Codein?

Official warnings indicate that abruptly stopping the medication after prolonged use, particularly in individuals who have developed physical dependence, can lead to withdrawal reactions. Discontinuation is typically described as a process that should be managed by a health professional, often through a slow dose tapering.

Q: Are there known risks for individuals who are poor metabolizers of Codeine?

Official regulatory documents note that individuals classified as CYP2D6 Poor Metabolizers convert codeine less effectively to its active form. This metabolic constraint may result in a diminished therapeutic effect for cough relief.

Q: Can this medication affect the results of drug screenings or tests?

The Guaifenesin component of the medication is known to potentially interfere with certain laboratory tests. This includes specific colorimetric assays for metabolites like VMA and 5-HIAA, which could lead to false test results.

Q: What is the difference between Resyl mit Codein syrup and tablets, if both exist?

Official documents confirm that different physical forms, such as liquid solutions (syrup/drops) and tablets, may be authorized. Regulatory information specifies different dosing units and different maximum daily limits depending on the specific form being administered.

How to Store and Dispose of Resyl mit Codein?

Strict storage and disposal requirements for Resyl mit Codein are documented in official regulatory labeling to maintain product stability and ensure safety.

Storage Conditions

Requirement	Specification
Temperature	Store below 25 C
Protection	Keep in the original outer carton to protect from light
Child Safety	Keep out of the sight and reach of children

Stability and Handling

Once the bottle is first opened, the medicine is stable for a period of 3 months. It must be kept in the original packaging until disposal.

Disposal Rules

Official instructions prohibit the disposal of this medicine via household waste or wastewater, which helps protect the environment. Unused or expired medication should be returned to a pharmacist for correct, regulated disposal.